Lanean...
PD‐1/PD‐L1 inhibitors in haematological malignancies: update 2017
The introduction of PD‐1/PD‐L1 pathway inhibitors is an important landmark in solid oncology with unprecedented practice‐changing activity in various types of solid tumours. Among haematological malignancies, PD‐1/PD‐L1 inhibitors have been successful, so far, only in the treatment of classical Hodg...
Gorde:
| Argitaratua izan da: | Immunology |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
John Wiley and Sons Inc.
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5629439/ https://ncbi.nlm.nih.gov/pubmed/28685821 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/imm.12788 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|